Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".
Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]
Theravance Biopharma (TBPH) had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a "buy" rating on the stock.